{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:23:26Z","timestamp":1791296606989,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T00:00:00Z","timestamp":1490313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T00:00:00Z","timestamp":1490313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>NKG2D is a major activating receptor of NK cells and plays a critical role in tumor immunosurveillance. NKG2D expression in NK cells is inhibited by the histone deacetylase (HDAC) inhibitor valproic acid (VPA) and enhanced by the narrow-spectrum HDAC inhibitor entinostat. We previously demonstrated that entinostat enhanced NKG2D transcription by increasing acetylation of Histones H3 and H4. However, the mechanism by which VPA reduces NKG2D expression in NK cells is not known. We have also shown that NKG2D transcription is regulated by STAT3 phosphorylation. In this study, we investigated regulation of NKG2D expression in NK cells by VPA and entinostat by assessing protein expression, phosphorylation, and interaction of HDACs and STAT3. We find that VPA selectively inhibits STAT3 tyrosine705 phosphorylation, but entinostat does not. STAT3 complexes with HDAC3, and HDAC3 inhibition represses STAT3 phosphorylation and therefore NKG2D expression. NK cells from STAT3 wild-type mice downregulate NKG2D in response to VPA, but not NK cells from STAT3 knockout mice. These results show that VPA is a potent inhibitor of STAT3 phosphorylation and demonstrate that histone acetylation and STAT3 tyrosine705 phosphorylation cooperate in regulating NKG2D expression in NK cells.<\/jats:p>","DOI":"10.1038\/srep45266","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T10:12:25Z","timestamp":1490350345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3"],"prefix":"10.1038","volume":"7","author":[{"given":"Lulu","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongya","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyuan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie S.","family":"Watowich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiguo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,24]]},"reference":[{"key":"BFsrep45266_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","volume":"23","author":"LL Lanier","year":"2005","unstructured":"Lanier, L. L. NK cell recognition. Annu Rev Immunol 23, 225\u2013274 (2005).","journal-title":"Annu Rev Immunol"},{"key":"BFsrep45266_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","volume":"28","author":"N Guerra","year":"2008","unstructured":"Guerra, N. et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28, 571\u2013580, doi: 10.1016\/j.immuni.2008.02.016 (2008).","journal-title":"Immunity"},{"key":"BFsrep45266_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc.2015.5","volume":"16","author":"MG Morvan","year":"2015","unstructured":"Morvan, M. G. & Lanier, L. L. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 16, 7\u201319, doi: 10.1038\/nrc.2015.5 (2015).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep45266_CR4","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1158\/0008-5472.CAN-11-2544","volume":"72","author":"G Pietra","year":"2012","unstructured":"Pietra, G. et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 72, 1407\u20131415, doi: 10.1158\/0008-5472.CAN-11-2544 (2012).","journal-title":"Cancer Res"},{"key":"BFsrep45266_CR5","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1073\/pnas.0730640100","volume":"100","author":"R Castriconi","year":"2003","unstructured":"Castriconi, R. et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100, 4120\u20134125, (2003).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep45266_CR6","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1182\/blood-2006-03-006700","volume":"108","author":"M Della Chiesa","year":"2006","unstructured":"Della Chiesa, M. et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 108, 4118\u20134125, doi: 10.1182\/blood-2006-03-006700 (2006).","journal-title":"Blood"},{"key":"BFsrep45266_CR7","doi-asserted-by":"publisher","first-page":"371832","DOI":"10.1155\/2011\/371832","volume":"2011","author":"A Peserico","year":"2011","unstructured":"Peserico, A. & Simone, C. Physical and functional HAT\/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol 2011, 371832, doi: 10.1155\/2011\/371832 (2011).","journal-title":"J Biomed Biotechnol"},{"key":"BFsrep45266_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1749-6632.2003.tb05964.x","volume":"983","author":"S Thiagalingam","year":"2003","unstructured":"Thiagalingam, S. et al. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 983, 84\u2013100 (2003).","journal-title":"Ann N Y Acad Sci"},{"key":"BFsrep45266_CR9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5, 769\u2013784 (2006).","journal-title":"Nat Rev Drug Discov"},{"key":"BFsrep45266_CR10","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1158\/0008-5472.CAN-04-4252","volume":"65","author":"S Armeanu","year":"2005","unstructured":"Armeanu, S. et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65, 6321\u20136329 (2005).","journal-title":"Cancer Res"},{"key":"BFsrep45266_CR11","doi-asserted-by":"publisher","first-page":"11136","DOI":"10.1158\/0008-5472.CAN-05-0599","volume":"65","author":"S Skov","year":"2005","unstructured":"Skov, S. et al. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 65, 11136\u201311145 (2005).","journal-title":"Cancer Res"},{"key":"BFsrep45266_CR12","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood-2007-07-101311","volume":"111","author":"S Diermayr","year":"2008","unstructured":"Diermayr, S. et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 111, 1428\u20131436, doi: 10.1182\/blood-2007-07-101311 (2008).","journal-title":"Blood"},{"key":"BFsrep45266_CR13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00262-008-0645-8","volume":"58","author":"C Zhang","year":"2009","unstructured":"Zhang, C., Wang, Y., Zhou, Z., Zhang, J. & Tian, Z. Sodium butyrate upregulates expression of NKG2D ligand MICA\/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother 58, 1275\u20131285, doi: 10.1007\/s00262-008-0645-8 (2009).","journal-title":"Cancer Immunol Immunother"},{"key":"BFsrep45266_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/1471-2407-14-370","volume":"14","author":"P Shi","year":"2014","unstructured":"Shi, P. et al. Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K\/Akt signaling pathway. BMC Cancer 14, 370, doi: 10.1186\/1471-2407-14-370 (2014).","journal-title":"BMC Cancer"},{"key":"BFsrep45266_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s11095-013-1231-0","volume":"32","author":"S Zhu","year":"2015","unstructured":"Zhu, S. et al. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharm Res 32, 779\u2013792, doi: 10.1007\/s11095-013-1231-0 (2015).","journal-title":"Pharm Res"},{"key":"BFsrep45266_CR16","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.febslet.2007.02.045","volume":"581","author":"H Ogbomo","year":"2007","unstructured":"Ogbomo, H., Michaelis, M., Kreuter, J., Doerr, H. W. & Cinatl, J. Jr. Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett 581, 1317\u20131322, doi: 10.1016\/j.febslet.2007.02.045 (2007).","journal-title":"FEBS Lett"},{"key":"BFsrep45266_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1189\/jlb.0711339","volume":"91","author":"LE Rossi","year":"2011","unstructured":"Rossi, L. E. et al. Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression. J Leukoc Biol 91, 321\u2013331, doi: 10.1189\/jlb.0711339 (2011).","journal-title":"J Leukoc Biol"},{"key":"BFsrep45266_CR18","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1073\/pnas.96.8.4592","volume":"96","author":"A Saito","year":"1999","unstructured":"Saito, A. et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96, 4592\u20134597 (1999).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep45266_CR19","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M Gottlicher","year":"2001","unstructured":"Gottlicher, M. et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20, 6969\u20136978, doi: 10.1093\/emboj\/20.24.6969 (2001).","journal-title":"EMBO J"},{"key":"BFsrep45266_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","volume":"294","author":"G Alter","year":"2004","unstructured":"Alter, G., Malenfant, J. M. & Altfeld, M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294, 15\u201322, doi: 10.1016\/j.jim.2004.08.008 (2004).","journal-title":"J Immunol Methods"},{"key":"BFsrep45266_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1182\/blood-2013-05-499707","volume":"124","author":"S Zhu","year":"2014","unstructured":"Zhu, S. et al. Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. Blood 124, 403\u2013411, doi: 10.1182\/blood-2013-05-499707 (2014).","journal-title":"Blood"},{"key":"BFsrep45266_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bcp.2016.03.010","volume":"108","author":"NG Leus","year":"2016","unstructured":"Leus, N. G. et al. HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-kappaB p65 transcriptional activity. Biochem Pharmacol 108, 58\u201374, doi: 10.1016\/j.bcp.2016.03.010 (2016).","journal-title":"Biochem Pharmacol"},{"key":"BFsrep45266_CR23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3892\/or.2016.4811","volume":"36","author":"Z Wang","year":"2016","unstructured":"Wang, Z. et al. HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. Oncol Rep 36, 589\u2013597, doi: 10.3892\/or.2016.4811 (2016).","journal-title":"Oncol Rep"},{"key":"BFsrep45266_CR24","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/leu.2008.9","volume":"22","author":"S Balasubramanian","year":"2008","unstructured":"Balasubramanian, S. et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22, 1026\u20131034, doi: 10.1038\/leu.2008.9 (2008).","journal-title":"Leukemia"},{"key":"BFsrep45266_CR25","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrc3818","volume":"14","author":"H Yu","year":"2014","unstructured":"Yu, H., Lee, H., Herrmann, A., Buettner, R. & Jove, R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14, 736\u2013746, doi: 10.1038\/nrc3818 (2014).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep45266_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11060-015-1731-3","volume":"123","author":"SD Ferguson","year":"2015","unstructured":"Ferguson, S. D., Srinivasan, V. M. & Heimberger, A. B. The role of STAT3 in tumor-mediated immune suppression. J Neurooncol 123, 385\u2013394, doi: 10.1007\/s11060-015-1731-3 (2015).","journal-title":"J Neurooncol"},{"key":"BFsrep45266_CR27","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1111\/febs.13285","volume":"282","author":"MS Wake","year":"2015","unstructured":"Wake, M. S. & Watson, C. J. STAT3 the oncogene - still eluding therapy? FEBS J 282, 2600\u20132611, doi: 10.1111\/febs.13285 (2015).","journal-title":"FEBS J"},{"key":"BFsrep45266_CR28","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1038\/leu.2011.340","volume":"26","author":"M Gupta","year":"2012","unstructured":"Gupta, M., Han, J. J., Stenson, M., Wellik, L. & Witzig, T. E. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 26, 1356\u20131364, doi: 10.1038\/leu.2011.340 (2012).","journal-title":"Leukemia"},{"key":"BFsrep45266_CR29","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1124\/jpet.103.055541","volume":"307","author":"E Hu","year":"2003","unstructured":"Hu, E. et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307, 720\u2013728 (2003).","journal-title":"J Pharmacol Exp Ther"},{"key":"BFsrep45266_CR30","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.imlet.2012.02.014","volume":"143","author":"X Liu","year":"2012","unstructured":"Liu, X. et al. Identification of microRNA transcriptome involved in human natural killer cell activation. Immunol Lett 143, 208\u2013217 (2012).","journal-title":"Immunol Lett"},{"key":"BFsrep45266_CR31","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1182\/blood-2006-02-003012","volume":"108","author":"AD Panopoulos","year":"2006","unstructured":"Panopoulos, A. D. et al. STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. Blood 108, 3682\u20133690, doi: 10.1182\/blood-2006-02-003012 (2006).","journal-title":"Blood"},{"key":"BFsrep45266_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/cei.12034","volume":"172","author":"X Wang","year":"2013","unstructured":"Wang, X. et al. Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation. Clin Exp Immunol 172, 104\u2013112, doi: 10.1111\/cei.12034 (2013).","journal-title":"Clin Exp Immunol"},{"key":"BFsrep45266_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.imbio.2008.02.006","volume":"213","author":"D Cholujova","year":"2008","unstructured":"Cholujova, D. et al. Comparative study of four fluorescent probes for evaluation of natural killer cell cytotoxicity assays. Immunobiology 213, 629\u2013640, doi: 10.1016\/j.imbio.2008.02.006 (2008).","journal-title":"Immunobiology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep45266.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep45266","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/srep45266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/srep45266.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T23:58:32Z","timestamp":1671839912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep45266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,24]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,5,31]]}},"alternative-id":["BFsrep45266"],"URL":"https:\/\/doi.org\/10.1038\/srep45266","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,24]]},"assertion":[{"value":"5 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45266"}}